Literature DB >> 24440459

Isolation and characterization of peptides with dipeptidyl peptidase-IV inhibitory activity from pepsin-treated bovine whey proteins.

Isabelle M E Lacroix1, Eunice C Y Li-Chan2.   

Abstract

Inhibition of the enzyme dipeptidyl peptidase (DPP)-IV is one of the strategies used for the treatment of type 2 diabetes. In the present study, pepsin-treated whey protein isolate (WPI) and α-lactalbumin displaying DPP-IV inhibitory activity were fractionated by successive chromatographic steps and the resulting active fractions analyzed for their constituent peptides by liquid chromatography-electrospray ionization-tandem mass spectrometry. Among the identified sequences, 24 peptides derived from α-lactalbumin and 11 from β-lactoglobulin were synthesized and their effects on DPP-IV activity assessed. The most potent fragments, LKPTPEGDL and LKPTPEGDLEIL (IC50=45 and 57 μM, respectively), were found to inhibit DPP-IV in an un-competitive manner. Although several of the peptides tested showed some inhibitory activity, only two were as effective as the un-fractionated WPI hydrolysate and none were as potent as the un-fractionated α-lactalbumin hydrolysate. The peptides' structural features, including length and amino acid composition, were found to impact their inhibitory activity. This study provides new insights on the active components responsible for the DPP-IV inhibitory activity of pepsin-treated whey proteins.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dipeptidyl peptidase-IV inhibitor; Mode of inhibition; Type 2 diabetes; α-Lactalbumin; β-Lactoglobulin

Mesh:

Substances:

Year:  2014        PMID: 24440459     DOI: 10.1016/j.peptides.2014.01.002

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  14 in total

Review 1.  Whey protein: The "whey" forward for treatment of type 2 diabetes?

Authors:  Linda E Mignone; Tongzhi Wu; Michael Horowitz; Christopher K Rayner
Journal:  World J Diabetes       Date:  2015-10-25

2.  Generation of dipeptidyl peptidase-IV-inhibiting peptides from β-lactoglobulin secreted by Lactococcus lactis.

Authors:  Suguru Shigemori; Kazushi Oshiro; Pengfei Wang; Yoshinari Yamamoto; Yeqin Wang; Takashi Sato; Yutaka Uyeno; Takeshi Shimosato
Journal:  Biomed Res Int       Date:  2014-08-03       Impact factor: 3.411

3.  Peptide array on cellulose support--a screening tool to identify peptides with dipeptidyl-peptidase IV inhibitory activity within the sequence of α-lactalbumin.

Authors:  Isabelle M E Lacroix; Eunice C Y Li-Chan
Journal:  Int J Mol Sci       Date:  2014-11-13       Impact factor: 5.923

4.  Utilization of blood by-products: An in silico and experimental combined study for BSA usage.

Authors:  Fátima Arrutia; Rebeca Fernández; Carlos Menéndez; Ulises A González; Francisco A Riera
Journal:  Sci Rep       Date:  2017-12-08       Impact factor: 4.379

Review 5.  Marine Peptides as Potential Agents for the Management of Type 2 Diabetes Mellitus-A Prospect.

Authors:  En-Qin Xia; Shan-Shan Zhu; Min-Jing He; Fei Luo; Cheng-Zhan Fu; Tang-Bin Zou
Journal:  Mar Drugs       Date:  2017-03-23       Impact factor: 5.118

6.  Hydrophobic interactions at subsite S1' of human dipeptidyl peptidase IV contribute significantly to the inhibitory effect of tripeptides.

Authors:  Mitsugu Araki; Norimasa Kanegawa; Hiroaki Iwata; Yukari Sagae; Keisuke Ito; Katsuyoshi Masuda; Yasushi Okuno
Journal:  Heliyon       Date:  2020-06-23

7.  Very high-protein and low-carbohydrate enteral nutrition formula and plasma glucose control in adults with type 2 diabetes mellitus: a randomized crossover trial.

Authors:  Maureen B Huhmann; Shinobu Yamamoto; Joel M Neutel; Sarah S Cohen; Juan B Ochoa Gautier
Journal:  Nutr Diabetes       Date:  2018-08-30       Impact factor: 5.097

Review 8.  Role of Bioactive Peptide Sequences in the Potential Impact of Dairy Protein Intake on Metabolic Health.

Authors:  Giovanni Tulipano
Journal:  Int J Mol Sci       Date:  2020-11-23       Impact factor: 5.923

9.  The development of bioactive peptides from dietary proteins as a dipeptidyl peptidase IV inhibitor for the management of type 2 diabetes.

Authors:  Chia-Ling Jao; Chuan-Chuan Hung; Yu-Shan Tung; Pei-Yi Lin; Meng-Chun Chen; Kuo-Chiang Hsu
Journal:  Biomedicine (Taipei)       Date:  2015-08-13

10.  Rapid Identification of Dipeptidyl Peptidase-IV (DPP-IV) Inhibitory Peptides from Ruditapes philippinarum Hydrolysate.

Authors:  Rui Liu; Lei Zhou; Yan Zhang; Nai-Juan Sheng; Zhi-Kang Wang; Ti-Zhi Wu; Xin-Zhi Wang; Hao Wu
Journal:  Molecules       Date:  2017-10-13       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.